Sandeep Jagtap: Presenting the Research Behind Pediatric Fondaparinux at ISTH 2026
Sandeep Jagtap, Senior Director, Global Clinical Strategy and Innovation at Viatris, shared a post on LinkedIn:
“Some scientific moments stay with you for a long time.
It was truly special to present one of our most cherished pieces of work at ISTH 2026 in Paris. This research on Arixtra (fondaparinux) contributed to its FDA approval for pediatric venous thromboembolism patients, helping address an area of significant unmet medical need.
Presenting this work on such a prestigious global platform was both humbling and deeply rewarding.
I am sincerely grateful to all the colleagues, investigators, and collaborators whose dedication and contributions made this work possible. It was a proud and memorable moment to see years of collective effort translated into meaningful progress for children.”
Stay Updated with the Latest ISTH 2026 Updates on Hemostasis Today.
-
Oct 18, 2026, 12:37Roberto C. Iglesias: Colon Cancer Prevention Beyond Supplements and Vitamins
-
Oct 18, 2026, 12:27Rafael Alejandro Camero Del Vecchio: Paroxysmal Nocturnal Hemoglobinuria Advancing Complement Inhibition with Ravulizumab
-
Oct 18, 2026, 12:26Abdul Mannan: When INR Misleads – Rethinking Bleeding Risk in Cirrhosis
-
Oct 18, 2026, 12:14Stéphane Laurent: The People and Technology Behind Safe Blood Transfusion
-
Oct 18, 2026, 12:14Abhi Kapuria: When VTE Prophylaxis Breaks Down in the ICU
-
Oct 18, 2026, 11:37Lee Anne Sorto: Beyond Compliance – Making Audits Count in Transfusion Safety
-
Oct 18, 2026, 11:26Valentina Ajello: Does ANH Benefit Women in Cardiac Surgery?
-
Oct 18, 2026, 11:06Alex Ballout: Novel FUT1 Variant Linked to a Rare H-Deficient Blood Phenotype
-
Oct 18, 2026, 10:51Lethukwenama Letsoalo: Why Women’s Iron Status Matters Before Childbirth